ClinicalTrials.gg

Program

ruxolitinib

Also written as “Ruxolitinib”, “Ruxolitinib cream” and “Ruxolitinib Cream”.

Its studies are mostly in Primary Myelofibrosis · Dermatitis, Atopic · Vitiligo · Graft vs Host Disease · Pancreatic Neoplasms, led by 3 companies.

Furthest: phase 4, since Jan 13, 202390 company-led studies, 14 open or runningNext primary completion: Dec 9, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte689 open or runningphase 4since Jan 13, 2023Jul 30, 2007Dec 9, 2026phase 1 · NCT07049575
Novartis214 open or runningphase 4since Mar 16, 2012Jul 6, 2009May 10, 2029phase 4 · NCT06824103
Suzhou Junjing BioSciences11 open or runningphase 2since Mar 27, 2025Mar 27, 2025Oct 31, 2027phase 2 · NCT06909136

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Apr 18, 2014.

  1. Mar 7, 2024Phase 1 study in Healthy ParticipantsIncyte · NCT06310304 · 24 enrolled · United States
  2. Apr 25, 2024Phase 2 study in Bronchiolitis Obliterans SyndromeIncyte · NCT06388564 · 130 enrolled · United States, Belgium, Canada and more
  3. Jun 5, 2024Phase 4 study in Steroid-refractory Acute Graft Versus Host DiseaseNovartis · NCT06462469 · 36 enrolled · China
  4. Aug 8, 2024Phase 3 study in NonSegmental VitiligoIncyte · NCT06548360 · 180 planned · United States, Canada
  5. Aug 12, 2024Phase 1 study in Healthy ParticipantsIncyte · NCT06555081 · 168 enrolled · United States
  6. Sep 6, 2024Phase 3 study in Graft vs Host DiseaseIncyte · NCT06615050 · 572 planned · United States
  7. Jan 27, 2025Phase 3 study in NonSegmental VitiligoIncyte · NCT06804811 · 250 planned · Argentina, Austria, Belgium and more
  8. Feb 4, 2025Phase 3 study in Dermatitis, AtopicIncyte · NCT06832618 · 159 enrolled · United States, Belgium, Canada and more
  9. Feb 4, 2025Phase 4 study in Graft vs Host DiseaseNovartis · NCT06824103 · 50 planned · China
  10. Mar 27, 2025Suzhou Junjing BioSciences's first study: phase 2 study in Intermediate- and High-risk Myelofibrosis (MF) Patients With SplenomegalyNew to Suzhou Junjing BioSciencesSuzhou Junjing BioSciences · NCT06909136 · 33 enrolled · China
  11. Apr 25, 20252 phase 3 studies in Hidradenitis SuppurativaIncyte · NCT06958211, NCT06959225
  12. Jun 25, 2025Phase 1 study in Hidradenitis SuppurativaIncyte · NCT07049575 · 24 planned · United States
  13. Jan 6, 2026Phase 1 study in Primary MyelofibrosisNovartis · NCT07340138 · 3 enrolled · Japan
  14. May 8, 2026Phase 1 study in Healthy ParticipantsIncyte · NCT07588139 · 24 enrolled · United States

Ahead

  1. Dec 9, 2026Primary completion: phase 1 study in Hidradenitis SuppurativaIncyte · NCT07049575
  2. Apr 30, 2027Primary completion: phase 3 study in NonSegmental VitiligoIncyte · NCT06804811
  3. Sep 30, 2027Primary completion: phase 2 study in Pancreatic NeoplasmsIncyte · NCT02955940
  4. Oct 31, 2027Primary completion: phase 2 study in Intermediate- and High-risk Myelofibrosis (MF) Patients With SplenomegalySuzhou Junjing BioSciences · NCT06909136

TargetBeta

“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
delgocitinibruleLEO Pharmaphase 321

Studies

The newest 60 of 90 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07588139Healthy Participants · United States1CompletedIncyteSep 8, 202624
NCT07340138Primary Myelofibrosis · Japan1Active, not recruitingNovartisJul 23, 20263
NCT07049575Hidradenitis Suppurativa · United States1RecruitingIncyteDec 9, 202624
NCT06959225Hidradenitis Suppurativa · United States, Bulgaria, Canada and more3Active, not recruitingIncyteOct 29, 2026580
NCT06958211Hidradenitis Suppurativa · United States, Belgium, Bulgaria and more3Active, not recruitingIncyteOct 1, 2026573
NCT06909136Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly · China2Active, not recruitingSuzhou Junjing BioSciencesOct 31, 202733
NCT06832618Dermatitis, Atopic · United States, Belgium, Canada and more3Active, not recruitingIncyteAug 7, 2026159
NCT06824103Graft vs Host Disease · China4RecruitingNovartisMay 10, 202950
NCT06804811NonSegmental Vitiligo · Argentina, Austria, Belgium and more3RecruitingIncyteApr 30, 2027250
NCT06615050Graft vs Host Disease · United States3RecruitingIncyteJan 17, 2031572
NCT06555081Healthy Participants · United States1CompletedIncyteOct 25, 2024168
NCT06548360NonSegmental Vitiligo · United States, Canada3RecruitingIncyteJun 5, 2028180
NCT06462469Steroid-refractory Acute Graft Versus Host Disease · China4Active, not recruitingNovartisSep 3, 202636
NCT06388564Bronchiolitis Obliterans Syndrome · United States, Belgium, Canada and more2Active, not recruitingIncyteOct 1, 2026130
NCT06310304Healthy Participants · United States1CompletedIncyteApr 16, 202424
NCT06238817Dermatitis, Atopic · United States, Australia, Belgium and more3CompletedIncyteMay 21, 2025241
NCT06213831Prurigo Nodularis · United States1CompletedIncyteJul 17, 202523
NCT05906628Eczema · United States, Canada, Germany and more2CompletedIncyteJul 15, 2024186
NCT05764161Prurigo · United States, Australia, Austria and more3CompletedIncyteDec 30, 2024190
NCT05750823Vitiligo · United States, Canada, France2CompletedIncyteMar 6, 202549
NCT05755438Prurigo · United States, Argentina, Belgium and more3CompletedIncyteOct 7, 2024204
NCT05696392Dermatitis, Atopic · United States4TerminatedIncyteJan 22, 202547
NCT05635838Hidradenitis Suppurativa · United States, Canada2CompletedIncyteOct 19, 202369
NCT05593445Lichen Sclerosus et Atrophicus · United States, Canada2CompletedIncyteSep 1, 202361
NCT05593432Lichen Planus · United States, Canada2CompletedIncyteOct 2, 202364
NCT05456529Dermatitis, Atopic · United States, Canada, Poland3CompletedIncyteMay 17, 2024103
NCT05247489Vitiligo · United States, Canada2CompletedIncyteDec 19, 202355
NCT05233410Eczema · United States, Bulgaria, Canada and more3WithdrawnIncyteApr 25, 20240
NCT05219864Eczema · United States, Canada, Czechia and more3WithdrawnIncyteApr 25, 20240
NCT05127421Dermatitis, Atopic · United States2CompletedIncyteAug 3, 202377
NCT05034822Dermatitis, Atopic · United States1CompletedIncyteAug 7, 202329
NCT04921969Dermatitis, Atopic · United States, Canada3CompletedIncyteMay 10, 2023330
NCT04896385Vitiligo · United States, Canada, France2CompletedIncyteNov 17, 202260
NCT04839380Dermatitis, Atopic · Canada2CompletedIncyteNov 18, 202249
NCT04530344Vitiligo · United States, Bulgaria, Canada and more3CompletedIncyteNov 14, 2022458
NCT04377620COVID-19 · United States, Russian Federation3TerminatedIncyteFeb 26, 2021211
NCT04362137Cytokine Release Syndrome · United States, Argentina, Brazil and more3CompletedNovartisOct 17, 2020432
NCT04057573Vitiligo · United States, Bulgaria, Canada and more3CompletedIncyteMar 15, 2021344
NCT04052425Vitiligo · United States, Bulgaria, Canada and more3CompletedIncyteMar 18, 2021330
NCT03920852Dermatitis, Atopic · United States, Canada1CompletedIncyteDec 26, 201941
NCT03774082Graft vs Host Disease · Brazil, Canada, Czechia and more2CompletedNovartisFeb 25, 202246
NCT03745651Dermatitis, Atopic · United States, Bulgaria, Canada and more3CompletedIncyteNov 18, 2019618
NCT03745638Dermatitis, Atopic · United States, Canada, France and more3CompletedIncyteDec 23, 2019631
NCT03491215Graft vs Host Disease · Belgium, Canada, Denmark and more2CompletedNovartisMar 11, 202145
NCT03257644Dermatitis, Atopic · United States1CompletedIncyteOct 7, 202070
NCT03123588Myeloproliferative Disorders · United States2TerminatedIncyteAug 3, 202012
NCT03112603Graft vs Host Disease · United States, Australia, Austria and more3CompletedIncyteMay 8, 2020330
NCT03099304Vitiligo · United States2CompletedIncyteSep 12, 2018157
NCT03011892Dermatitis, Atopic · United States, Canada2CompletedIncyteJan 10, 2018307
NCT02955940Pancreatic Neoplasms · United States, Poland2Active, not recruitingIncyteSep 30, 202710
NCT02953678Graft vs Host Disease · United States2CompletedIncyteJan 31, 201871
NCT02966353Primary Myelofibrosis · Austria, Belgium, Bulgaria and more2CompletedNovartisJul 24, 201851
NCT02913261Graft vs Host Disease · Australia, Austria, Bulgaria and more3CompletedNovartisJun 24, 2019310
NCT02723994Leukemia · United States, Canada, Puerto Rico2CompletedIncyteMar 3, 2026171
NCT02598297Primary Myelofibrosis · Australia, Austria, Belgium and more3TerminatedNovartisOct 23, 201749
NCT02553330Alopecia Areata · United States2TerminatedIncyteOct 3, 201790
NCT02386800Primary Myelofibrosis · Australia, Belgium, Bulgaria and more4Active, not recruitingNovartisApr 5, 2032279
NCT02292446Polycythemia Vera · Austria, Belgium, Bulgaria and more3CompletedNovartisDec 29, 2017161
NCT02253277Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany1CompletedNovartisMar 6, 20185
NCT02120417Breast Neoplasms · United States, France, Italy and more2TerminatedIncyteFeb 2016149

How it is read

Names in the registry

  • “Ruxolitinib”, 44 entries
  • “Ruxolitinib cream”, 14 entries
  • “Ruxolitinib Cream”, 11 entries
  • “ruxolitinib”, 6 entries
  • “Ruxolitinib phosphate cream”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.